Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

1.63USD
23 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.63
Open
$1.62
Day's High
$1.63
Day's Low
$1.62
Volume
620
Avg. Vol
17,166
52-wk High
$6.43
52-wk Low
$1.45

Select another date:

Tue, Apr 24 2018

BRIEF-Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility

* CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING

BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Announces Registered Direct Offering

* CESCA THERAPEUTICS INC - ‍PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO 609,636 SHARES OF STOCK AT A PURCHASE PRICE OF $2.27 PER SHARE​ Source text for Eikon: Further company coverage:

BRIEF-Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing

* CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES

BRIEF-Cesca Therapeutics Files For Common Stock Offering Of Up To $15 Mln

* FILES FOR COMMON STOCK OFFERING OF UP TO $15 MILLION - SEC FILING Source text: (http://bit.ly/2E1uKu2) Further company coverage:

BRIEF-Cesca Therapeutics Announces Proposed Public Offering Of Common Stock

* CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics appoints Joe Balagot as senior vice president of corporate development

* Cesca Therapeutics appoints healthcare investment banking veteran Joe E. Balagot as senior vice president of corporate development Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics reports quarterly loss per share $0.24

* Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update

Select another date: